Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells $772,331.60 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Thursday, January 8th, Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.89, for a total transaction of $502,680.00.
• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $45.37 on Friday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.25 and a 1-year high of $46.65. The stock has a market cap of $3.44 billion, a P/E ratio of 100.82 and a beta of 0.06. The firm has a fifty day moving average price of $42.21 and a 200 day moving average price of $38.85.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors have recently made changes to their positions in the stock. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $32,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $36,000. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. The Goldman Sachs Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.